Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar
24 February 2023 - 3:40AM
Business Wire
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a
commercially oriented Research and Development company committed to
scientific innovation for preventing and combating metabolic and
cardiovascular diseases, today publishes its 2023 Letter to
Shareholders including its 2023 financial calendar.
In this new edition you will find:
- The message from Sébastien PELTIER, CEO and co-founder of
Valbiotis, to shareholders, who provide invaluable support at a
time of strategic acceleration;
- An overview of the next key milestones: the results of the
Phase II/III REVERSE-IT clinical study on TOTUM•63 in prediabetes,
the signature of licensing and/or distribution partnerships with
major regional or global nutrition and health players,
internationally for TOTUM•070 (LDL cholesterol) and proprietary
marketing of TOTUM•070 in France;
- Insights on: the dietary supplement market, TOTUM•070's
positioning, advances in CSR, the R&D program on
micro-algae;
- Stock market information on Valbiotis shares.
Valbiotis also announces its financial calendar for 2023:
- March 15: publication of the 2022 Annual Report;
- May 2: Annual General Meeting (participation details to be
announced);
- September 28: publication of the 2023 Half-Yearly Report.
You can find all the relevant information, such as financial
reports, general meeting documents, stock exchange data, letters to
shareholders, the corporate presentation and the universal
registration document on the Company's website www.valbiotis.com,
in the "Investors" section
(https://www.valbiotis.com/investisseurs).
Due to environmental considerations, as part of our commitments,
our “Letter to Shareholders” will now be offered in digital format
only: Letter to Shareholders No.6.
About Valbiotis
Valbiotis is a commercially oriented Research & Development
company, committed to scientific innovation for preventing and
combating metabolic and cardiovascular diseases in response to
unmet medical needs. Valbiotis has adopted an innovative approach,
aiming to revolutionize healthcare by developing a new class of
health nutrition products designed to reduce the risk of major
metabolic diseases, relying on a multi-target strategy enabled by
the use of plant-based terrestrial and marine resources.
Internationally, its products are intended to be the subject of
licensing and/or distribution agreements with global or regional
health and nutrition players. In France, Valbiotis will be
responsible for marketing its own products. Created at the
beginning of 2014 in La Rochelle, the Company has forged numerous
partnerships with leading academic centers. The Company has
established three sites in France – Périgny, La Rochelle (17) and
Riom (63) – and a subsidiary in Quebec City (Canada). Valbiotis is
a member of the "BPI Excellence" network and has been recognized as
an "Innovative Company" by the BPI label. Valbiotis has also been
awarded "Young Innovative Company" status and has received major
financial support from the European Union for its research programs
via the European Regional Development Fund (ERDF). Valbiotis is a
PEA-SME eligible company. For more information about Valbiotis,
please visit: www.valbiotis.com
Name: Valbiotis ISIN code: FR0013254851
Mnemonic code: ALVAL EnterNext© PEA-PME 150
This press release contains forward-looking statements about
Valbiotis’ objectives. Valbiotis considers that these projections
are based on rational hypotheses and the information available to
Valbiotis at the present time. However, in no way does this
constitute a guarantee of future performance, and these projections
may be affected by changes in economic conditions and financial
markets, as well as certain risks and uncertainties, including
those described in the Valbiotis Universal Registration Document
filed to the French Financial Markets Regulator (AMF) on May 19,
2022, and completed by an amendment on November 8, 2022. This
document is available on the Company’s website (www.valbiotis.com).
This press release and the information it contains do not
constitute an offer to sell or subscribe, or a solicitation to
purchase or subscribe to Valbiotis’ shares or financial securities
in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230223005567/en/
Corporate communication / Valbiotis Carole Rocher Communication
and Public Affairs Director + 33 6 77 82 56 88
Marc Delaunay Communication Manager media@valbiotis.com
Financial communication / Seitosei Actifin Stéphane Ruiz
Associate Director +33 1 56 88 11 14 sruiz@actifin.fr
Valbiotis (EU:ALVAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valbiotis (EU:ALVAL)
Historical Stock Chart
From May 2023 to May 2024